|
A message from our partners at Equiscreen
This has been disseminated on behalf of Oncolytics Biotech ONCY Is a Small Cap Nasdaq Biotech Turning up the Heat With FDA Momentum 
Oncolytics Biotech (NASDAQ: ONCY) is starting to separate itself from a crowded biotech field thanks to pelareorep, its first-in-class dsRNA immunotherapy platform that’s producing unusually strong data in some of the hardest GI cancers to treat. The company recently scored a major win after aligning with the FDA on a pivotal trial design for metastatic anal cancer, putting ONCY on a clearer regulatory path moving forward. But the real headline grabber has been the colorectal cancer data. Pelareorep showed a 19.5-month median duration of response in KRAS-mutant MSS colorectal cancer — massively outperforming the typical 4–6 month benchmark seen with current therapies. Add in a 33% response rate and 27-month median overall survival, and investors are starting to view ONCY as more than just another early-stage biotech story. What makes the platform especially interesting is that pelareorep appears designed to tackle the exact reason immunotherapy has historically struggled in GI cancers. Instead of relying solely on checkpoint inhibitors, pelareorep works to activate the immune system and “heat up” tumors that are normally resistant to treatment. With multiple Fast Track designations, over 1,200 patients treated, and billion-dollar market opportunities across colorectal, pancreatic, and anal cancers, ONCY is building a story centered around both massive unmet need and potentially game-changing durability data. If upcoming studies continue delivering results like these, pelareorep could emerge as one of the more disruptive immunotherapy platforms in the GI oncology space. WITH REAL CANCER DATA AND FDA TRACTION, ONCY DESERVES A SPOT ON YOUR WATCHLIST!
More Reading from MarketBeat.com
AutoZone's Pullback Sets Up a Long-Term Buying OpportunitySubmitted by Thomas Hughes. Originally Published: 5/26/2026. 
AutoZone (NYSE: AZO) is a buy-and-hold quality stock that is nearly beyond compare. The company’s management, strategy, market position, industry trends, operational quality, cash flow, and capital returns form a recipe for steadily rising value, as reflected in its long-term price action. AZO’s stock price advanced approximately 500% from the pandemic low to the 2025 peak, and additional highs are still likely in 2026. The takeaway in 2026 is that AZO is experiencing a much-needed price correction and setting up a buying opportunity of generational proportions. It may take some time for AZO’s market to regain traction and resume its uptrend, but it will, and when it does, the gains could be explosive. Catalysts include international expansion, market share gains, business optimization, and aggressive share buybacks.
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states.
The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now. See which companies control the supply chain behind this emerging tech
The company is expanding aggressively in Latin America, particularly in Mexico and Brazil, where middle-class growth is strongest. At the same time, management is focused on capturing the fragmented commercial auto parts market and improving supply chain efficiency through digitization. The critical factors remain earnings growth, cash flow, and aggressive share repurchases. AutoZone is widely regarded as an efficient steward of capital, reducing its share count significantly on both a quarterly and annual basis. Q1 activity amounted to $586 million, or about 92% of operating profits, reducing the share count by an average of 2% on a trailing 12-month (TTM) basis. Mixed Results Favor AutoZone InvestorsAutoZone reported a mixed quarter, with revenue for its fiscal Q3 2026 falling short of the consensus estimate. However, the $20 million miss was modest and easily overlooked in light of 8.5% growth and margin strength. Revenue growth was supported by increases in store count in the U.S., Mexico, and Brazil, along with a 3.9% systemwide comp. Comparable sales rose 4.1% domestically and 1.6% internationally, below expectations but still a healthy gain. Margin news was also mixed, which helped drive the stock price decline. Even so, the gross margin compression and overall impact were less severe than feared, leaving operating profit up approximately 6.5% year over year and GAAP earnings per share well ahead of the consensus forecast. At $38.07, GAAP earnings were nearly $2 above expectations and 5.5% better than expected, enough to sustain operations and capital returns while supporting the company’s strategy. AutoZone’s balance sheet shows no red flags. The company’s cash balance held relatively steady despite increased investment and robust capital returns. Other highlights include higher inventory and total assets, along with a reduction in deficit. Normally a concern, the shareholder deficit is a result of share buybacks and is likely to persist over time. AutoZone has returned more than $12.5 billion to investors over the past decade, approximately 25% of its late-May market cap. AutoZone Market Overreacts to Results: Deepens Value OpportunityAnalyst trends have contributed to AutoZone’s 2026 stock price weakness, as some price targets were lowered early in the year. The caveat is that the market overreacted to those adjustments, compounding the decline after the fiscal Q3 release in late May. Trading near $3,000, AZO stock is 20% below the lowest price target tracked, while analyst consensus points to more than 40% upside. The most likely outcome is that AZO finds a bottom in late Q2 or early Q3 and begins to regain traction later in the year. Institutional trends are among the reasons AZO stock appears to be nearing a bottom. Institutional investors own approximately 93% of the shares and have been net buyers on a trailing 12-month basis. Price action in late May has entered the range where institutional buying was strongest, suggesting a robust response from this group could be forthcoming. If not, AZO’s stock price could enter a sustained downtrend, but that is not indicated by the results, analyst trends, or chart action. 
The chart shows a mid-term downtrend, but the odds of a rebound are increasing. Even as the price moves lower, the MACD is diverging and the stochastic is deeply oversold, suggesting bears have lost control and bulls need only a catalyst to step in. That could be as simple as the valuation, which points to a 50% discount to the five-year outlook, though it may require more tangible news. That may not arrive until the company releases its fiscal Q4 earnings results. The biggest risk for AutoZone this year is margin compression. While the effects of aggressive expansion are manageable and will moderate over time, rising costs are a greater concern and may continue to weigh on results. The question is whether efficiencies gained from the “Mega Hub” strategy will be enough to support margin recovery over time. |
